SAN CARLOS, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 13,030,000 shares of common stock at a public…Read More
Vaxcyte Announces Closing of 575 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares
